source
- AstraZeneca reports Phase 3 trial shows Imfinzi-Padcev combo improves survival in bladder cancerAstraZeneca announced that its Phase 3 study of the immunotherapy Imfinzi combined with the antibody‑drug conjugate Padcev, developed with Pfizer and Astellas, extended overall survival for patient…
- BeOne secures FDA approval for lymphoma therapyBeOne received FDA approval for its lymphoma therapy, a notable achievement in a crowded therapeutic area. The agency’s review concluded that the treatment meets safety and efficacy standards, pla…